Journal of the Korean Medical Association (대한의사협회지)

Korean Medical Association (대한의사협회)
권호 표지
DOI QR코드

DOI QR Code

Cutaneous melanoma

피부흑색종

  • Lee, Seok-Jong (Department of Dermatology, Kyungpook National University School of Medicine) ;
  • Lee, Soo Jung (Department of Internal Medicine, Kyungpook National University School of Medicine)
  • 이석종 (경북대학교 의과대학 피부과학교실) ;
  • 이수정 (경북대학교 의과대학 내과학교실)
  • Received : 2018.10.15
  • Accepted : 2018.10.16
  • Published : 2018.11.20
⟨ Previous Next ⟩

Abstract

The cutaneous melanoma has been regarded as rare disease entity in Korea for long time but it shows a silent growth recently. Furthermore the management of cutaneous melanoma including staging system, surgical principle, sentinel lymph node biopsy and subsequent complete node dissection and, most importantly, immunotherapy and target therapy against cutaneous melanoma recently. The incidence of cutaneous melanoma is steadily increasing in Korea but its increase is rapid recent 2 decades to 4.3 times and should be greater soon according to the steeper increase of life expectancy. New staging system proposed by American Joint Committee on Cancer (2017) includes changes in individual TNM category and stage groups, particularly from a prognostic viewpoint. Dermoscopy has been successfully introduced in the differential diagnosis of pigmented skin lesion focusing on cutaneous melanoma by non-invasive simple diagnostic tool. Sentinel lymph node biopsy was a issue of long debate whether survival benefit is real or not. Temporary conclusion about this question is reached after two large scale studies and immediate complete node dissection should be performed in a certain situations. Most important change is drug therapy focusing on immunotherapy and target therapy. Braf- and MEK-inhibitor, immune checkpoint inhibitor and PD-1 blocker has been proved to be effective as a sole or combination regimen against advanced and/or high-risk adjuvant setting of cutaneous melanoma. In conclusion, these remarkable changes will be reviewed shortly here.

Keywords

References

  1. Knackstedt T, Knackstedt RW, Couto R, Gastman B. Malig-nant melanoma: diagnostic and management update. Plast Reconstr Surg 2018;142:202e-216e. https://doi.org/10.1097/PRS.0000000000004571
  2. Gershenwald JE, Scolyer RA, Hess KR, Thompson JF, Long GV, Ross MI. Melanoma of the skin. In: Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DC, Jessup JM, Brierley JD, Gaspar LE, Schilsky RL, Balch CM, Winchester DP, Asare EA, Madera M, Gress DM, Meyer LR, editors. AJCC cancer staging manual. 8th ed. New York: Springer; 2017. p. 563-585.
  3. Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, Lazar AJ, Faries MB, Kirkwood JM, McArthur GA, Haydu LE, Eggermont AMM, Flaherty KT, Balch CM, Thompson JF; for members of the American Joint Committee on Cancer Melanoma Expert Panel and the International Melanoma Database and Discovery Platform. Melanoma staging: evidence-based changes in the American Joint Com-mittee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2017;67:472-492. https://doi.org/10.3322/caac.21409
  4. Malvehy J, Puig S, Argenziano G, Marghoob AA, Soyer HP; International Dermoscopy Society Board members. Dermo-scopy report: proposal for standardization: results of a consen-sus meeting of the International Dermoscopy Society. J Am Acad Dermatol 2007;57:84-95. https://doi.org/10.1016/j.jaad.2006.02.051
  5. Saida T, Miyazaki A, Oguchi S, Ishihara Y, Yamazaki Y, Murase S, Yoshikawa S, Tsuchida T, Kawabata Y, Tamaki K. Significance of dermoscopic patterns in detecting malignant melanoma on acral volar skin: results of a multicenter study in Japan. Arch Dermatol 2004;140:1233-1238.
  6. Koga H, Saida T, Uhara H. Key point in dermoscopic differen-tiation between early nail apparatus melanoma and benign longitudinal melanonychia. J Dermatol 2011;38:45-52. https://doi.org/10.1111/j.1346-8138.2010.01175.x
  7. Conic RZ, Cabrera CI, Khorana AA, Gastman BR. Determi-nation of the impact of melanoma surgical timing on survival using the National Cancer Database. J Am Acad Dermatol 2018;78:40-46. https://doi.org/10.1016/j.jaad.2017.08.039
  8. Bichakjian CK, Halpern AC, Johnson TM, Foote Hood A, Grichnik JM, Swetter SM, Tsao H, Barbosa VH, Chuang TY, Duvic M, Ho VC, Sober AJ, Beutner KR, Bhushan R, Smith Begolka W; American Academy of Dermatology. Guidelines of care for the management of primary cutaneous melanoma. American Academy of Dermatology. J Am Acad Dermatol 2011;65:1032-1047. https://doi.org/10.1016/j.jaad.2011.04.031
  9. Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm FK, Foshag LJ, Cochran AJ. Technical details of intra-operative lymphatic mapping for early stage melanoma. Arch Surg 1992;127:392-399. https://doi.org/10.1001/archsurg.1992.01420040034005
  10. Faries MB, Thompson JF, Cochran AJ, Andtbacka RH, Mozzillo N, Zager JS, Jahkola T, Bowles TL, Testori A, Beitsch PD, Hoekstra HJ, Moncrieff M, Ingvar C, Wouters MWJM, Sabel MS, Levine EA, Agnese D, Henderson M, Dummer R, Rossi CR, Neves RI, Trocha SD, Wright F, Byrd DR, Matter M, Hsueh E, MacKenzie-Ross A, Johnson DB, Terheyden P, Berger AC, Huston TL, Wayne JD, Smithers BM, Neuman HB, Schneebaum S, Gershenwald JE, Ariyan CE, Desai DC, Jacobs L, McMasters KM, Gesierich A, Hersey P, Bines SD, Kane JM, Barth RJ, McKinnon G, Farma JM, Schultz E, Vidal-Sicart S, Hoefer RA, Lewis JM, Scheri R, Kelley MC, Nieweg OE, Noyes RD, Hoon DSB, Wang HJ, Elashoff DA, Elashoff RM. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med 2017;376:2211-2222. https://doi.org/10.1056/NEJMoa1613210
  11. Swick JM, Maize JC Sr. Molecular biology of melanoma. J Am Acad Dermatol 2012;67:1049-1054. https://doi.org/10.1016/j.jaad.2011.06.047
  12. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-2516. https://doi.org/10.1056/NEJMoa1103782
  13. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, Kudchadkar R, Burris HA 3rd, Falchook G, Algazi A, Lewis K, Long GV, Puzanov I, Lebowitz P, Singh A, Little S, Sun P, Allred A, Ouellet D, Kim KB, Patel K, Weber J. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012;367:1694-1703. https://doi.org/10.1056/NEJMoa1210093
  14. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. Improved survival with ipili-mumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-723. https://doi.org/10.1056/NEJMoa1003466
  15. Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank C, Petrella TM, Hamid O, Zhou H, Ebbinghaus S, Ibrahim N, Robert C. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet 2017;390:1853-1862. https://doi.org/10.1016/S0140-6736(17)31601-X
  16. Larkin J, Hodi FS, Wolchok JD. Combined nivolumab and ipi-limumab or monotherapy in untreated melanoma. N Engl J Med 2015;373:1270-1271. https://doi.org/10.1056/NEJMc1509660
  17. Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, Patt D, Chen TT, Berman DM, Wolchok JD. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 2015;33:1889-1894. https://doi.org/10.1200/JCO.2014.56.2736